Praveen Tipirneni, Morphic Therapeutic CEO
‘Dawn of oral therapy’: Morphic touts UC data in march toward Takeda’s Entyvio
The ulcerative colitis R&D space is heating up once again, as Morphic Therapeutic touted positive mid-stage data for its oral med.
At week 12, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
